// App-Quantinova.ai

37 GP19.09 : Management of pasireotide-induced hyperglycaemia with proactive monitoring and early intervention: key learnings from the phase III, 24-week PAOLA study

Researchers

Presenter

  • Thierry Brue

Principal Investigators

  • Maria Fleseriu

  • Ilan Shimon

  • Karina Hermosillo Resendiz

  • Albert Kandra

  • Alberto M Pedroncelli

  • Annamaria Colao

Medical Centers

  • Dipartimento di Medicina Clinica e Chirurgia, Universit Federico II di Napoli, Naples, Italy

  • Hopital de la Timone, Aix-Marseille University, Centre National de la Recherche Scientifique, and Assistance Publique-Hopitaux de Marseille, Marseille, France

  • Division of Endocrinology, Medical School and Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  • Rabin Medical Center and Sackler School of Medicine, Tel-Aviv University, Petah-Tiqva, Israel

Locations

  • France

  • Brazil

  • Italy

  • Israel

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Adrenomedullin

  • Protein Tyrosine Phosphatase, Receptor Type F

  • Hemoglobin A1c

Drug/Treatment

  • Pasireotide

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved